Archive


Category: ~$1.04B

  • Lilly to Acquire Prevail Therapeutics for ~$1.04B

    Shots: Lilly to acquire Prevail for $22.50/ share in cash (~ $880M) payable at closing plus one non-tradable CVR worth up to $4.00/ share in cash (~160M), making a total of $26.50/share in cash (~$1.040B). The transaction is expected to be close in Q1’21 The CVR is payable upon the first regulatory approval of a […]